- Language: English
- 678 Pages
- Published: December 2012
Global Immunology Partnering 2010-2015: Deal trends, players and financials
- ID: 2229059
- June 2015
- Region: Global
- 1000 Pages
The Global Immunology Partnering 2010-2015 report provides an understanding and access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter immunology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors immunology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest immunology agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all immunology partnering deals announced since 2010 including financial terms where available including over 700 links to online deal records of actual immunology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of the report provide an orientation of immunology dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in immunology deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.
A popular section with readers; chapter 3 covers the average financial deal terms for deals signed in the immunology field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.
Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in immunology partnering and dealmaking since 2010.
Chapter 4 covers the leading immunology deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active immunology deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma and biotech companies.
Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the immunology partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus.
In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the immunology field preparing them with everything they need to know about partnering in the research, development and commercialization of immunology technologies and products.
A full appendix is provided at the very end of the report which lists all the immunology deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged. The appendix is useful for looking at all the deals signed by one specific company.
Global Immunology Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to immunology trends and structure of deals entered into by leading companies worldwide.
Global Immunology Partnering 2010-2015 includes:
Trends in immunology dealmaking in the biopharma industry since 2010
Analysis of immunology deal structure
Access to headline, upfront, milestone and royalty data
Access to over 700 immunology deal records
The leading immunology deals by value since 2010
In Global Immunology Partnering 2010-2015, the available deals are listed by:
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Immunology Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 700 immunology deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law? SHOW LESS READ MORE >
Chapter 1 - Introduction
Chapter 2 - Trends in immunology dealmaking
2.2. Immunology partnering over the years
2.3. Immunology partnering by deal type
2.4. Immunology partnering by industry sector
2.5. Immunology partnering by stage of development
2.6. Partnering by immunology specific technology type
Chapter 3 - Average financial deal terms for immunology partnering
3.2. Disclosed financials terms for immunology partnering
3.3 Immunology partnering headline values
3.4 Immunology deal upfront payments
3.5 Immunology deal milestone payments
3.6 Immunology royalty rates
Chapter 4 - Leading immunology deals
4.1. Most active in immunology partnering
4.2. Top immunology deals by value
4.3. Big pharma immunology dealmaking activity
4.4. Big biotech immunology dealmaking activity
Chapter 5 - Immunology contracts directory
5.2. Immunology partnering by company A-Z
5.3. Immunology partnering stage of development
5.4. Immunology partnering by deal type
5.6. Immunology partnering by technology type
Appendix 1 - Directory of immunology deals by company A-Z 2010-2015-
Appendix 2 - Directory of immunology deals by stage of development 2010-2015
Appendix 3 - Directory of immunology deals by deal type 2010-2015
Appendix 4 - Directory of immunology deals by therapy area 2010-2015
Appendix 5 - Immunology partnering resource center
Table of figures
Figure 1: Immunology partnering since 2010
Figure 2: Immunology partnering by deal type since 2010
Figure 3: Immunology partnering by industry sector since 2010
Figure 4: Immunology partnering by stage of development since 2010
Figure 5: Immunology partnering by disease type since 2010
Figure 6: Immunology partnering by specific technology type since 2010
Figure 7: Immunology deals with a headline value - by stage of development
Figure 8: Immunology deals with upfront payment values - by stage of development
Figure 9: Immunology deals with milestone payment - by stage of development
Figure 10: Immunology deals with royalty rates
Figure 11: Active immunology dealmaking activity- 2010 to 2015
Figure 12: Top immunology deals by value since 2010
Figure 13: Big pharma - top 50 - immunology deals 2010 to 2015
Figure 14: Big pharma immunology deal frequency - 2010 to 2015
Figure 15: Big biotech - top 50 - immunology deals 2010 to 2015
Figure 16: Big biotech immunology deal frequency - 2010 to 2015
Figure 17: Online partnering resources
Figure 18: Forthcoming partnering events